Press Release: STADA welcomes Pedersen as General Counsel
- Bild-Infos
- Download
Ein Dokument
STADA welcomes Pedersen as General Counsel
- Ole Wendler Pedersen joins STADA as Executive Vice President Legal and General Counsel
- Pedersen benefits from more than 20 years of international legal experience, latterly as Group General Counsel for Lundbeck, and in leadership roles at Novo Nordisk
- STADA CEO Peter Goldschmidt: “Ole brings a strategic and operational business focus, ranging from R&D and manufacturing to commercial functions and overseeing complex merger and acquisition processes."
Bad Vilbel, Germany – 3 December 2025 – STADA has welcomed Ole Wendler Pedersen as Executive Vice President Legal and General Counsel, effective from 1 December 2025. He takes over from Christoph Dengler who, after almost 14 years with STADA, has left to pursue career opportunities outside the organization.
A Danish national, Pedersen is based at the group’s headquarters in Bad Vilbel, near Frankfurt, Germany, reporting directly to CEO Peter Goldschmidt as a member of the STADA Executive Committee (SEC).
Pedersen benefits from more than 20 years of international legal experience, latterly as Group General Counsel for Lundbeck, a global and publicly listed pharmaceutical company developing and commercializing innovative treatments for brain diseases, where he led globally Legal, Compliance, Corporate Governance, and Trademarks. Prior to his position at Lundbeck, Pedersen served in multiple leadership roles with Novo Nordisk across several regions, most recently as Regional General Counsel, Vice President of Legal, Compliance & Quality for Novo Nordisk Europe.
“Ole brings a strategic and operational business focus, ranging from R&D and manufacturing to commercial functions and overseeing complex merger and acquisition processes,” Goldschmidt stated. “His significant experience of organizational build-out and transformational leadership across different therapeutic areas and regions will further strengthen Legal as an essential business function within STADA.“
Pedersen stated: “I am thrilled to be joining STADA at this exciting time. It is a company with a strong heritage, clear purpose, and bold growth ambitions for the future. I look forward to leading the global legal function as an integral part of the business ̵ enabling growth, fostering innovation, and supporting our teams in delivering trusted healthcare solutions.”
Wishing Christoph Dengler the very best for his next chapter, Goldschmidt concluded: “Christoph has led the Legal function, including compliance, IP and risk-management, with great engagement and creative thinking in contributing significantly to STADA's growth. He was instrumental in navigating the legal complexities of the Bain Capital and Cinven acquisition in 2017 and equally played a key role in preparing our transition to CapVest, the expected closing of which will mark the successful conclusion of a major phase for STADA.”
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group sales of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.
Additional information for journalists STADA Arzneimittel AG - Media Relations Stadastrasse 2-18, 61118 Bad Vilbel - Germany Phone: +49 (0) 6101 603-165 E-Mail: press@stada.de Or visit us via our website at https://www.stada.com/media/newsroom Follow @stadaGroup on LinkedIn Additional information for capital market participants STADA Arzneimittel AG - Investor & Creditor Relations Stadastrasse 2-18, 61118 Bad Vilbel – Germany Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215 E-mail: ir@stada.de Or visit us via our website at https://www.stada.com/investor-relations/